Marg brings a deep understanding of the Canadian market access environment.

She can navigate requirements and nuances of health technology reimbursement submissions and the research supporting them.

This has been developed through extensive experience leading health economic, health outcomes and other research to support market access in a wide range of therapeutic areas.

Experience developed through increasing responsibility in several contract research environments.

Marg’s substantial experience includes:

• effectiveness of innovative health technologies such as emotional freedom techniques.
• cost-effectiveness model development and adaptations for Canada and other countries (e.g. Australia, US, UK);
• budget impact analyses for national health technology assessment as well as public and private formularies;
• evidence synthesis (targeted and systematic review and network meta-analysis);
• health utility measurement, including patient reported outcome measure plan for trial design;
• analysis of observational and prospectively collected data; and
• trial-based economic evaluations.